Drug Channels Archive for October, 2025

Click a link below to view the mailing archive as if it had been sent to you.

2025-10-30 07:47		Drug Channels - As Pharma Faces Financial Pressure, Pharmacy Delivers Measurable Impact
2025-10-29 07:53		Drug Channels - Cigna's Rebate-Free Pharmacy Model: Three Realities Behind Its Latest Push to Pop the Gross-to-Net Bubble
2025-10-28 07:51		Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D's Decline, 340Bloat, and Dr. G's ACIP Haunting
2025-10-24 07:47		Drug Channels - Let's Be DIRECT: We Have an Access and Affordability Problem to Solve
2025-10-21 07:47		Drug Channels - The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers' Vertical Integration with Physician Practices
2025-10-20 07:47		Drug Channels - Informa Connect's Trade and Channel Strategies
2025-10-17 07:47		Drug Channels - Why Site of Care Is the Hidden Barrier in Neurology's Bright Pipeline
2025-10-15 08:07		Request Your Invitation: 2026 Drug Channels Leadership Forum
2025-10-14 07:51		Drug Channels - NOW AVAILABLE: The 2025–26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
2025-10-13 07:47		Drug Channels - Informa Connect's Pharma/Biotech GTN Summit
2025-10-10 08:15		Drug Channels - Direct-to-Patient 2.0: Why Today's DTP Programs Can't Scale—and What Pharma Must Do Next
2025-10-09 07:58		Drug Channels - The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip (rerun)
2025-10-08 07:58		Drug Channels - 2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access (rerun)
2025-10-07 08:02		Drug Channels - The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market (rerun)
2025-10-06 07:47		Drug Channels - Informa Connect's PBM Contracting Summit
2025-10-03 08:05		Drug Channels - Reimagining Patient Access: Building Direct-to-Consumer Models for a New Regulatory Era

<< Archive Index • Subscribe >>